Cynthia X. Ma, MD, PhD

home / authors / cynthia-x-ma-md-phd

Articles

22 Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer

Sara A. Hurvitz, MD;Anne F. Schott, MD;Cynthia X. Ma, MD, PhD;Rita Nanda, MD;George Zahrah;Natasha Hunter, MD;Antoinette R. Tan;Melinda L. Telli, MD;Jesus Anampa Mesias;Rinath M. Jeselsohn;Pamela N. Munster, MD;Eric Zhi;Elizabeth Duperret;Cecile Mather;Erika P. Hamilton, MD;Hyo S Han

August 4th 2024

4 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/ Metastatic Triple-Negative Breast Cancer (a/mTNBC): Updated Results From BEGONIA, a Phase 1b/2 Study

Jamil Asselah;Cynthia X. Ma, MD, PhD;Zbigniew Nowecki;Robert Huisden;Ross Stewart;Petra Vuković;Peter Schmid, MD

April 28th 2023

Cynthia Ma, MD, PhD, Discusses Results From a Phase 2 Trial of Neratinib/Fulvestrant in HER2-Mutant Breast Cancer

Cynthia X. Ma, MD, PhD

July 22nd 2021

Cynthia Ma, MD, PhD, explains key efficacy findings regarding HER-targeted therapy to treat patients with HER2-mutant breast cancer.

Cynthia Ma, MD, PhD, Discusses HER2-Targeted Therapy for Patients with HER2-Mutant Breast Cancer

Cynthia X. Ma, MD, PhD

July 12th 2021

An expert in treating breast cancer discusses potential therapy options for patients with HER2-mutant.

Cynthia X. Ma, MD, PhD, on Benefits of Attendance at AACR

Cynthia X. Ma, MD, PhD

May 30th 2021

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, following the American Association for Cancer Research Annual Meeting 2021 about the benefits of the meeting to clinical trial investigators.

Cynthia X. Ma, MD, PhD, on Potential Immunotherapy Options for Patients With Metastatic Breast Cancer

Cynthia X. Ma, MD, PhD

May 22nd 2021

CancerNetwork® spoke with Cynthia X. Ma, MD, PhD, during the American Association for Cancer Research Annual Meeting 2021 about data supporting the potential use of the exemestane/leuprolide acetate plus pembrolizumab combination.

The Cancer Genome Atlas: Clinical Applications for Breast Cancer

Cynthia X. Ma, MD, PhD;Matthew J. Ellis, MD, PhD, FRCP

December 15th 2013

This article aims to provide an overview of The Cancer Genome Atlas findings, with a particular focus on their potential biological relevance and therapeutic implications.

The Natural History of Hormone Receptor–Positive Breast Cancer: Attempting to Decipher an Intriguing Concept

Gayathri Nagaraj, MD;Matthew J. Ellis, MD, PhD, FRCP;Cynthia X. Ma, MD, PhD

August 10th 2012

It is time to develop more active treatments in the early-disease setting that actually eradicate ER-positive breast cancer before new mutations and secondary resistance have a chance to develop. In this regard, standard chemotherapy is not the answer.

PARP Inhibitors and Their Evolving Role in Breast Cancer

Ryan P. Roop, MD;Cynthia X. Ma, MD, PhD;Matthew J. Ellis, MD, PhD, FRCP

October 12th 2011

Poly(adenosine diphosphate [ADP]–ribose) polymerase (PARP) inhibitors are designed to exploit the “synthetic lethality” concept for cancer therapy.

Predicting Endocrine Therapy Responsiveness in Breast Cancer

Cynthia X. Ma, MD, PhD;Cesar G. Sanchez, MD;Matthew J. Ellis, MD, PhD, FRCP

February 15th 2009

This article reviews ongoing progress in the effort to identify predictors of endocrine therapy responsiveness for breast cancer and discusses the value of “pre-treatment” vs “on-treatment” tumor profiling for predicting outcomes.